INmune Bio reported a net loss of $45.9 million for 2025, compared to $42.1 million in 20241
The company holds $24.8 million in cash with runway extending through Q1 20271
CORDStrom MAA filing to UK MHRA is planned for mid-summer 2026, with subsequent EMA and expected U.S. BLA in Q4 20261
FDA alignment was achieved for an adaptive Phase 2b/3 pathway for XPro in early Alzheimer's disease1
The company recorded a $16.5 million impairment of acquired intellectual property and development1
INmune Bio sold 4.30 million shares in 2025 for $27.5 million in net proceeds1
R&D expenses totaled $20.7 million in 2025, compared to $33.2 million in 20241
The company received an Australian R&D rebate of $5.2 million AUD ($3.6 million USD) in January 20261
INmune Bio has three main pipeline products:
CORDStrom™, XPro™ (a Dominant-Negative TNF platform), and INKmune® (a cell-based cancer medicine)1
CEO David Moss stated the company has transitioned from a mid-stage clinical company into a late-stage, registration-directed organization1
Sources:
1. https://markets.businessinsider.com/news/stocks/inmune-bio-inc-announces-2025-results-and-provides-business-update-1035978078